anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Determining pace or speed based on the sensor data may include determining an amount of contact time of a user&#39;s foot with an exercise surface, such as the ground. The contact time may be determined by determining samples of the sensor data that correspond to various events such as heelstrike, toe-off, and subsequent heelstrike. In one example, these events may be determined by determining a sequence (e.g., a triplet) of three sample values that exceed a corresponding threshold. The validity of the determined triplet (e.g., heelstrike, toe-off, and heelstrike) may be confirmed by determining whether the difference between the final event sample and the intermediate event sample is greater than the difference between the intermediate event sample and the initial event sample. After validation, the contact time may be determined from the triplet. The speed or pace may then be determined using a linear or non-linear relationship to the contact time.
The present invention discloses a kind of Chinese medicine composition for treating tumor. The Chinese medicine composition consists of alkaloid extracted from flavescent sophora root and oleanolic acid and other triterperic acid compound extracted from privet fruit in certain ratio. Of the Chinese medicine composition, the flavescent sophora root extract contains flavescent sophora alkaloid in 50-100 %, and the privet fruit extract has oleanolic acid content in triterperic acid compounds in 50-99.5 %. The components in the Chinese medicine composition can generate synergistic effect. The experiment on S180 sarcoma and Lewis lung cancer in animal&#39;s body and other pharacodynamic experiment show that the Chinese medicine composition has effect of reducing leucopenia and other tumor radiotherapy and chemotherapy toxic side effects. The Chinese medicine composition may be used by patient regularly.
PROBLEM TO BE SOLVED: To obtain the subject compound effective for inhibiting the skin exuberance and growth of tumor cell. and useful for the treatment of hypertrophic dermatosis such as psoriasis, neoplastic diseases such as leukemia, sebaceous diseases such as acne and seborrheic dermatitis, etc. SOLUTION: This compound is expressed by the formula I (R is hydroxy and both R&#39; and R&#39;&#39; are H at the same time or together form =CH2 or R is H or fluorine and R&#39; and R&#34; together form =CH2 ). Most preferable compound is 1,25-dihydroxy-16,22S,23-trienecholecalciferol or 1,25-dihydroxy-16,22R,23- trienecholecalciferol. The compound of the formula I can be produced e.g. by using a compound of the formula II (R&lt;4&gt; and R&lt;6&gt; are each a lower alkyl; R&lt;5&gt; is a lower alkyl, an aryl, etc.) as a starting substance and eliminating a silyl- protecting group from a silylated diol or trial corresponding to the formula I in the final stage.
PURPOSE: To provide a bone replacement material whose biological activity is made as close to that of an endogenous hone transplant as possible by including polypeptides having the biological action of fibroblast growth factors in a porous substrate to form a bone replacement material. CONSTITUTION: One or more polypeptides having the biological action o fibroblast growth factors are contained in a porous substrate to form a bone replacement material. Further, basic fibroblast growth factors and acidic fibroblast growth factors are contained. The acidic fibroblast growth factors prepared by recombination method are contained, and the muteins of the fibroblast growth factors are also contained. Further, from 1 ng/cm&lt;3&gt; to 1 mg/cm&lt;3&gt; , preferably from 1 to 100 μg/cm&lt;3&gt; , polypeptides are contained, and the porous substrate is formed by an inorganic, preferably bioactive, material. The porous inorganic substrate is essentially made from inorganic calcium and is essentially made from calcium phosphate.
NEW MATERIAL:A substance having the following physical and chemical properties. Elementary analysis value (%): H 6.75, C 45.28, N 13.63. Specific rotatory power: [alpha]D&lt;30&gt;=-76.6. Solubility: easily soluble in water, 0.01N HCl and 0.01N NaOH. Color reaction: positive in biuret reaction, copper-Folin&#39;s reaction. Appearance: white powder, and its aqueous solution is colorless. Molecular weight: about 60 kilodalton. USE:Having lymphoma growth effect, useful for preparing a physiologically active substance (e.g., interferon) by an animal cell (e.g., namarupa cell, or melanoma cell). PROCESS:Grown bovine serum is gelled with glacial acetic acid, the gel is homogenized and centrifuged to give a supernatant liquid. The supernatant liquid is dialyzed to remove acetic acid, ultrafiltered, lyophilized, the dried material is suspended in a base medium for cultivating an animal cell, an active ingredient is extracted a soluble part is subjected to gel filtratin, and the active ingredient is purified to give the desired substance.
The invention comprises quinoxaline derivatives of the general formula &lt;FORM:0914303/IV (b)/1&gt; wherein R1 is a hydrogen or halogen atom or an alkyl or haloalkyl radical containing up to 6 carbon atoms, an alkoxy radical with up to 6 carbon atoms or a nitro radical, R2 is an alkyl radical with up to 4 carbon atoms, an aralkyl or aryl radical, R3 is an alkoxy radical with up to 6 carbon atoms or a &lt;FORM:0914303/IV (b)/2&gt; radical and X and Y are oxygen or sulphur. These quinoxalines may be prepared by reacting the appropriate 2-mercapto-quinoxaline with phosgene, thiophosgene, a chloro-formic acid ester or a thiocarbonic ester halide preferably in inert solvents e.g. alkaline solutions with an acid binding agent being present. Specified binding agents are alkali and alkaline earth metal hydroxides and carbonates and tertiary amines.  In Example 1, 2-thiocarboxyethyl-3-methoxy-quinoxaline is prepared by adding ethyl chloroformate to an alkaline solution of 3-methoxy-2-mercapto-quinoxaline.  In Example 2, a compound of formula &lt;FORM:0914303/IV (b)/3&gt; is prepared by adding thiophosgene to 3-methoxy-2-mercapto quinoxaline in alkaline solution.  In Example 3 a compound of formula &lt;FORM:0914303/IV (b)/4&gt; is prepared as above using phosgene in place of thiophosgene. These compounds are used as fungicides (see Group VI). Specification 885,789 is referred to.ALSO:Pesticidal compositions contain as active ingredient a quinoxaline of formula &lt;FORM:0914303/VI/1&gt; wherein R1 is a hydrogen or halogen atom, an alkyl, haloalkyl or alkoxy radical with up to 6 carbon atoms or a nitro radical, R2 is an alkyl radical with up to 4 carbon atoms, an aralkyl or aryl radical, R3 is an alkoxy radical with up to 6 carbon atoms or a &lt;FORM:0914303/VI/2&gt; radical and X and Y are oxygen or sulphur.  These quinoxalines may be used in a concentration of 0.00001 to 1%, diluted or extended with solid or liquid carriers.  Specified solid carriers are talc, chalk, bentonite and clay and specified liquid carriers are water, alcohols, especially methanol and ethanol, ketones, especially acetone and methyl ethyl ketone and liquid hydrocarbons.  The quinoxalines may be used in combination with each other or with known insecticides and/or fertilizers.  A quinoxaline of formula &lt;FORM:0914303/VI/3&gt; was dissolved in acetone, benzene hydroxy diphenyl polyglycol ether as emulsifier was added and the mixture diluted with water to give a solution containing 0.02% of the quinoxaline.  Bush beans infested with eggs of the two-spotted spider were sprayed with an aqueous emulsion as prepared above.  Specification 885,789 is referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a Bacillus natto culture extract-containing preparation which prevents the discoloration (black coloration) of the preparation, the characteristic smell of fermented soybeans, and the deterioration of active ingredients such as natto kinase in the Bacillus natto culture extract, and to provide a method for effectively preserving the Bacillus natto culture extract.  &lt;P&gt;SOLUTION: This Bacillus natto culture extract-containing preparation comprises the Bacillus natto culture extract and either of a reducing sugar and a reducing sugar derivative. The reducing sugar derivative is preferably a reducing sugar derivative not having a reducing terminal. Since having a discoloration-inhibiting effect, the Bacillus natto culture extract-containing preparation is especially effective for a transparent capsule preparation. In addition, the deterioration of the Bacillus natto culture extract can be prevented by mixing the Bacillus natto culture extract with the and either of the reducing sugar and the reducing sugar derivative and then preserving the mixture.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Methods for cerebral and systemic cooling via a patient&#39;s nasopharyngeal cavity are described. In one method, a cooling assembly is inserted into a nasal cavity through a patient&#39;s nostril. A substantially dry gas is delivered through a lumen of the catheter onto the surface of the patient&#39;s nasal cavity. Evaporative heat loss cools the patient&#39;s nasal cavity. If additional cooling is needed, a liquid coolant is delivered through a separated lumen of the catheter. The liquid coolant is nebulized at a plurality of delivery ports on the distal end of the catheter and is delivered onto the surface of the patient&#39;s nasal cavity in combination with the dry gas. The dry gas enhances evaporation of the nebulized coolant and additional cooling is provided from the evaporative heat loss of the liquid coolant.
Disclosed herein are compounds of the general formula X-A-B-C&#39;-Y wherein X is lower alkanoyl optionally substituted with one or two hydroxyls, A is an amino acid residue having a lower alkyl side chain, e.g. Ala or Val, B is a non-peptide linking unit, e.g. statyl or Phe~[CH2NH]Leu, C&#39; is an amino acid residue of .alpha.-amino-.beta.-cycloalkylpropionic acid, glutamic acid or .alpha.-aminoadipic acid, or a related derivative thereof, and Y is alkoxy, cycloalkoxy, a substituted alkoxy or a substituted amino group, e.g. cycloalkylalkoxy, arylalkoxy, alkylamino, (cycloalkyl)alkylamino or arylalkylamino. The compounds inhibit the activity of human immuno-deficiency virus (HIV) protease and interfere with HIV induced cytopathogenic effects in human cells. These properties render the compounds useful for combating HIV infections.
According to the latest relevant foreign case analysis reports and clinical trial results, the TIP regimen remains the recommended treatment for patients with recurrent and refractory malignant germ-cell tumors based on previous data. Carboplatin has been proven effective and less toxic in children with MGCTs, while cisplatin is more commonly used in early stages. In our research group\&#39;s previously explored TIC scheme (albumin paclitaxel + ifosfamide + carboplatin), cisplatin is often substituted with carboplatin. Additionally, albumin paclitaxel replaces traditional paclitaxel due to its lower adverse reaction rate and higher tumor tissue uptake accumulation, forming the TIC regimen. Our preliminary clinical work has shown that the TIC regimen effectively improves remission rates of recurrent refractory germ cell tumors, particularly yolk sac tumors. For a small number of children who are not responsive to the TIC regimen, combining Sirolimus (an mTOR inhibitor) significantly enhances remission rates of recurrent refractory yolk sac tumors. This approach can potentially lead to cure or achieve surgery and radiotherapy within a curative timeframe. Therefore, this study aims to determine the efficacy of combining mTOR inhibitor Sirolimus with the TIC chemotherapy regimen (albumin-paclitaxel + isocyclophosphamide + carboplatin) in treating recurrent or refractory vitelline cyst tumors, providing a novel and effective therapeutic option for children with recurrent and refractory MGCTs.
An IgM human monoclonal antibody (HuMAb), JWCI L94, that reacts to a human melanoma cell line was developed using B cells obtained from a melanoma patient. Screening of expression libraries from 2 melanoma cell lines revealed a number of immunoreactive clones that all shared the carboxyl (C) terminal sequence alanine proline (Ala-Pro). HuMAb L94 reacted not only to C-terminal Ala-Pro-containing fusion proteins but also to the synthetic dipeptide Ala-Pro. Also disclosed is the cross-reactivity of HuMAb L94 with peptides containing a C-terminal Gly-Pro or Pro-Pro. The epitope of human monoclonal antibody L94, reacting with human tumors was defined as the peptides with the C-terminal sequence alanine-proline (Ala-Pro). A synthetic peptide with such a sequence, RVAALARDAP, SEQ ID NO:13, was evaluated for its immunogenicity and shown to significantly increase cytotoxicity of melanoma patients&#39; PBMC after in vivo immunization with melanoma cell vaccines (MCV). In vitro restimulation of a vaccinated patient&#39;s PBMC with the peptide also enhanced cytotoxicity against autologous peptide-pulsed BCL. This cytotoxicity was specific to the C-terminal sequence Ala-Pro.
Rheumatoid arthritis is a chronic debilitating disease. Muscle weakness is a common symptom in patients with rheumatoid arthritis (RA). From a metabolic perspective, muscle mass is determined by the balance between protein synthesis and degradation. People with RA note tenderness, stiffness, and pain in affected muscles.

In RA, chronic inflammation is a primary driver of muscle weakness. Persistent synovitis leads to the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which contribute to muscle atrophy and dysfunction. Joint damage and pain further limit physical activity, exacerbating muscle wasting through disuse atrophy. Additionally, the systemic inflammation associated with RA can lead to metabolic disturbances, including insulin resistance, which negatively impacts muscle protein synthesis and overall muscle health.

RA can cause a 25% to 70% reduction in muscular strength, typically caused by decreased skeletal muscle mass, ,Reduced muscle strength is usually considered to be a result of decreased muscle mass due to disuse atrophy. Rheumatoid cachexia, a term used in RA, is defined as a loss of skeletal muscle mass and with no, or little weight loss in fat mass Muscle weakness not only reduces the quality of life for the affected patients, but since patients\&amp;#39; ability to work decreases it will also dramatically increase the burden on society (e.g. increased costs for long-term sick leave). Thus, RA severely affects both the individual and the society Given the complexity of muscle affection in RA , accurate assessment is essential for effective management. Conventional clinical methods, such as manual muscle testing and grip strength measurements, provide limited information on the underlying causes of muscle weakness. Advanced imaging techniques, such as conventional ultrasound (US) and shear wave elastography (SWE), offer a more comprehensive evaluation by providing detailed information on muscle morphology and stiffness.
The invention relates to use of a pro-inflammatory agent such as IL-8 or muramyl dipeptide (MDP) for the manufacture of a medicament for Crohn&#39;s disease. Preferably the pro-inflammatory agent is a neutrophil chemoattractant. Preferably the pro- inflammatory agent is EL-8. The invention also relates to a method of treating Crohn&#39;s disease in a subject, said method comprising administering to said subject an effective amount of a pro-inflammatory agent such as IL-8, and to IL-8 for use in the treatment of Crohn&#39;s disease. The invention also relates to products comprising IL-8 for topical treatment. The invention also relates to methods for determining the responsiveness of a subject to MDP comprising determining the CARD15 genotype of the subject.
PURPOSE:To efficiently obtain the compound useful as a raw material for compounded perfumes, etc., by treating a 12-hydroxy-8alpha,12-epoxy-13,14,15,16- tetranorlabdane compound with a Wittig&#39;s reagent in the presence of a base in a solvent and subsequently subjecting the reaction. product to a thermal ring-closing reaction. CONSTITUTION:An optically active 12-hydroxy-8alpha,12-epoxy-13,14,15,16- tetranorlabdane of formula I (the waved line exhibits the cis or trans isomer) is reacted with a Wittig&#39;s reagent of formula II (R is methyl, ethyl; Ph is phenyl; X is halogen) (e.g. methoxymethyltriphenylphosphonium chloride) in the presence of a base (e.g. sodium hydride) in an organic solvent (e.g. dimethyl sulfoxide), and the formed optically active 8alpha-hydroxy-13-alkoxy-14,15,16-trinorlabda-12-ene compound of formula III is subjected to a thermal ring-closing reaction in the presence of an acid to obtain (-)-8alpha,13-epoxy-14,15,16-trinorlabda-12-ene of formula IV.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition that improves pharmacokinetic characteristics of a therapeutic component.  &lt;P&gt;SOLUTION: There is provided a composition, including a therapeutic component and an efficacy enhancing component, that improves pharmacokinetic characteristics of the therapeutic component. The therapeutic component may include α-2-adrenergic agonist, and the efficacy enhancing component may include a fatty acid. In one embodiment, the therapeutic component and the efficacy enhancing component form a complex. The efficacy enhancing component is selected from the group consisting of anionic polymers, saturated fatty acids, unsaturated fatty acids and mixtures thereof. Specifically, the efficacy enhancing component is linolenic acid, and the therapeutic component is brimonidine.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To support execution of input work which puts a smaller load on an operator who inputs a prescription order.  &lt;P&gt;SOLUTION: The disease name of a patient is obtained. Out of a disease name-classified prescription history data base 202 storing disease names, medicine identifiers for identifying medicines, and the total number of prescriptions of the medicine made by a plurality of doctors for the disease names in association with one another, the medicine identifier and the total number of prescriptions associated with the obtained disease name are extracted as first extraction information. Out of a doctor-classified prescription history data base 203 storing the medicine identifiers and the individual number of times of prescriptions made by a doctor in association with one another, for each doctor identifier for identifying the doctor who prescribes to the patient among a plurality of doctors, the medicine identifier and the individual number of times of prescriptions associated with the doctor identifier are extracted as second extraction information. On the basis of the first extraction information and the second extraction information, a display method in displaying medicine identifiers on a display device 116 that the doctor views is determined.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an adhesive skin patch that contains a medication other than bisoprolol, is suppressed in the occurrence of oozing or squeezing-out of the components of the self-adhesive layer of the adhesive skin patch from the exposed section of the self-adhesive layer and in the reduction of a medication content due to the oozing of the medication from the self-adhesive layer, which occur while the adhesive skin patch is stored.  &lt;P&gt;SOLUTION: Each of the adhesive skin patch, a support, a peeling liner and the self-adhesive layer has a rectangular planer shape, projecting sections being provided on each of the support-side surface at the corners of the adhesive skin patch. Moreover, it is possible to provide the center section and the circumferential section in the adhesive skin patch and to provide projecting sections at the corners of the rectangular shape of the center section. Furthermore, it is possible to provide, between two or more adjacent projecting sections, raised connecting sections where the adhesive skin patch is thinner than in the projecting sections. If providing a back split section in the peeling liner, the back split section is made to avoid passing through the projecting sections in the rectangular corners.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a weakly acidic skin detergent, foaming continuously, excellent in cleansing property and without having a tight skin feeling after finishing the cleansing.  &lt;P&gt;SOLUTION: This weakly acidic skin detergent is provided by including an amphoteric surfactant as a main component, and further a fatty acid salt and a polyhydric alcohol. Since the weakly acidic skin detergent is excellent in cleansing property, and since the foaming by the amphoteric surfactant which is a main component, is maintained even on continuing the cleansing, the amount of amphoteric surfactant required for cleansing is less and also there is no flowing out of the detergent by the collapse of the foam. In addition, since its pH is weakly acidic which is close to that of the skin, the detergent has gentle-to-skin characteristics i.e. irritation to the skin is low and further it is excellent even in the comparison of the tight skin feelings after the cleansing.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To separate a cysteine protease inhibitory protein gene being a new gene of Bacillus natto, to breed a bacterium of the genus Bacillus including Bacillus natto or Bacillus subtilis having more excellent cysteine protease inhibitory activity by improving an existing Bacillus natto or the gene, Escherichia coli or yeast, to provide a method for efficiently producing a cysteine protease inhibitory protein-containing composition by using the microorganism and a method useful in prevention or treatment for diseases caused by cysteine protease.  &lt;P&gt;SOLUTION: The new cysteine protease inhibitory protein is obtained. The gene encoding the cysteine protease inhibitory protein is obtained. The transformant is recombined with the gene. The method for producing a composition containing the protein is provided. The prophylactic or ameliorant for diseases caused by cysteine protease is obtained.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PCT No. PCT/JP92/01157 Sec. 371 Date Sep. 24, 1993 Sec. 102(e) Date Sep. 24, 1993 PCT Filed Sep. 10, 1992 PCT Pub. No. WO93/04712 PCT Pub. Date Mar. 18, 1993This invention relates to a preparation comprising a transparent syringe body or container, which has been obtained by molding a resin comprising, as a base material, a propylene polymer, and as a nucleating agent, a phosphoric ester represented by the following general formula (1):    &lt;IMAGE&gt;  (1)  and a drug solution charged into the syringe body or container. The preparation is excellent in transparency, free from the dissolution of additives for the resin into the drug solution charged therein even when the drug solution remains charged for a long period of time and hence high in safety. The preparation is useful, in particular, as a syringe preparation charged with a drug solution therein.